Amyloid Beta Kinetics and Enhancing the Diagnostic and Prognostic Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease


The pathological process of Alzheimer’s disease begins decades before cognitive decline. It has become apparent that for disease-modifying therapies to be effective, early intervention is required. In order to screen those at risk, improved biomarkers of AD pathology are urgently needed to identify individuals early, while damage is not too severe and is potentially reversible. We are using the most advanced technology to identify a new generation of biomarkers.

Funding to Date



Biomarkers/Diagnostics/Studies of Risk & Resilience, Foundational


Randall J. Bateman, M.D.

Norelle Wildburger, Ph.D.

Related Content: